Status:
UNKNOWN
CMR or Angiography for FFR-guided Revascularisation
Lead Sponsor:
Karolinska Institutet
Conditions:
STEMI
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Around 50% of patients that present with ST Elevation Myocardial Infarction (STEMI) have residual disease in the non-culprit lesions. If the residual disease should be treated, what should guide inter...
Detailed Description
Early reperfusion of epicardial coronaries is essential for salvage of ischemic myocardium, reducing both morbidity and mortality in patients with ST elevation myocardial infarction (STEMI). Current E...
Eligibility Criteria
Inclusion
- Patients included in the active arm of FULL REVASC, that has not undergone invasive FFR, and give written informed consent.
Exclusion
- Asthma/Chronic Obstructive Pulmonary Disease, systolic blood pressure under 90 mmHg, bradycardia (less than 45 beats/min), persistent second or third AtrioVentricular-block, Sick Sinus Syndrome, Long QT Syndrome, atrial fibrillation, severe aortic stenosis, severe heart failure (NHYA class III-IV), metallic implants, kidney failure (less than 30 ml/min/1.73 square meters body surface area), current treatment with the drugs Persantin, theophyllamin or Fevarin.
Key Trial Info
Start Date :
January 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03408912
Start Date
January 26 2018
End Date
December 1 2024
Last Update
June 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska University Hospital
Stockholm, Solna, Sweden, 171 76